Skip to main content
main-content

Melanoma and skin cancers: Immunotherapy

Journal articles and book chapters

02-04-2019 | Immunotherapy | Video | Article

Researcher comment: The impact of lifestyle factors on the gut microbiome and immunotherapy response

Christine Spencer outlines her study investigating the effect of diet and supplements on gut microbiota and response to anti-PD-1 therapy in patients with metastatic melanoma, and discusses how the findings may be relevant to other tumor types (3:43).

28-01-2019 | Melanoma | Editorial | Article

IDO inhibitors in advanced melanoma: A path forward?

On the back of success in melanoma with PD-1 and CTLA-4 checkpoint inhibitors, attention has turned to other checkpoint proteins such as indoleamine 2,3-dioxygenase (IDO). In this editorial, Zeynep Eroglu (Moffitt Cancer Center, USA) discusses the advances and setbacks in the development of IDO inhibitors for melanoma.

12-12-2018 | Immunotherapy | Feature | Article

Hyperprogression as a response to immunotherapy: ‘A serious downside’

In light of recent reports of hyperprogression in response to treatment with cancer immunotherapy, medwireNews spoke to medical oncologist Razelle Kurzrock (University of California, San Diego, La Jolla, USA) about the phenomenon, the implications for therapy, and future directions for research.

20-08-2018 | Metastatic melanoma | Article

Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma

Auslander N et al. Nat Med 2018; 24: 1545–1549.

05-06-2018 | Radiotherapy | Article

Safety of combining radiotherapy with immune-checkpoint inhibition

Hwang WL et al. Nat Rev Clin Oncol 2018. doi: 10.1038/s41571-018-0046-7

04-06-2018 | Cutaneous squamous cell carcinoma | Article

PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma

Migden MR et al. N Engl J Med 2018. doi:10.1056/NEJMoa1805131

10-04-2018 | Response criteria | Article

iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics

Seymour L et al. Lancet Oncol 2017; 18(3): e143–e152. doi:10.1016/S1470-2045(17)30074-8

07-03-2018 | Immunotherapy | Article

Gastrointestinal toxicity of immune checkpoint inhibitors: from mechanisms to management

Samaan MA et al. Nat Rev Gastroenterol Hepatol 2018; 15:222–234. doi:10.1038/nrgastro.2018.1

06-03-2018 | Immunotherapy | Article

Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges

Fukumura et al. Nat Rev Clin Oncol 2018. doi:10.1038/nrclinonc.2018.29

16-02-2018 | Immunotherapy | Article

Using immunotherapy to boost the abscopal effect

Ngwa W et al. Nat Rev Cancer 2018; 18: 313–322. doi:10.1038/nrc.2018.6

05-10-2017 | Melanoma | Article

Ipilimumab and early signs of pulmonary toxicity in patients with metastastic melanoma: a prospective observational study

Franzen D et al. Cancer Immunol Immunother 2017. doi: 10.1007/s00262-017-2071-2

27-06-2017 | Checkpoint blockade | Article

Monitoring immune-checkpoint blockade: response evaluation and biomarker development

Nishino M et al. Nat Rev Clin Oncol 2017; 14: 655–668. doi:10.1038/nrclinonc.2017.88

21-03-2017 | Basal cell carcinoma | Article

Basal cell carcinoma: PD-L1/PD-1 checkpoint expression and tumor regression after PD-1 blockade

Evan J et al. J Immunotherapy Cancer 2017; 5: 23. doi:10.1186/s40425-017-0228-3

07-03-2017 | CNS metastases | Article

Comparing available criteria for measuring brain metastasis response to immunotherapy

Here we report a comparison between available response criteria when used to evaluate CNS response of patients from a Phase II trial studying the effect of pembrolizumab in patients with previously untreated or progressive melanoma or lung cancer brain metastases.

Qian JM et al. J Neurooncol 2017. doi:10.1007/s11060-017-2398-8

04-06-2016 | Non-melanoma skin cancer | Article

Management of high-risk squamous cell carcinoma of the skin

Fu T, Aasi SZ, & Hollmig ST. Curr Treat Options in Oncol 2016; 17: 34. doi:10.1007/s11864-016-0408-2

Image Credits